Nephrol Dial Transplant (2002) 17: 2-8
© 2002 European Renal Association-European Dialysis and Transplant Association
The role of trace elements in uraemic toxicity
University Hospital Gent, Department of Internal Medicine, Nephrology Division, De Pintelaan 185, B 9000 Gent, Belgium
Abstract
Although most research on uraemic toxicity has focused on the retention or removal of organic solutes, subtle changes in the concentration of inorganic compounds are also of importance because these compounds may have significant clinical consequences. Potential clinical implications include increased risk of cancer, cardiovascular disease, immune deficiency, anaemia, renal function impairment and bone disease. In uraemic patients, the most important factor affecting trace element concentration is the degree of renal failure and modality of renal replacement therapy. Accumulation of trace elements in haemodialysis patients has resulted from dialysate contaminated with aluminium and strontium. Several trace elements have been implicated in the decline of renal function. These include arsenic, cadmium, copper, germanium, lead and mercury. In uraemic patients, aluminium, cadmium, chromium, lanthanum, strontium and zinc have been shown to accumulate in bone. In addition to substantial evidence linking aluminium to renal osteodystrophy, studies have also implicated cadmium, iron and strontium in bone disease. Studies using a rat model of chronic renal failure have demonstrated an association between lanthanum accumulation and mineralization defects characteristic of osteomalacia. Investigations of arsenic accumulation in animal models have demonstrated that speciation of trace elements potentially may alter toxicities of trace elements accumulated in uraemic patients. Conversely, the presence of uraemic toxins may also alter the uptake and toxicity of certain trace elements. Although research in uraemic patients has focused primarily on total concentrations of trace elements, the evolution of both inorganic and organic species should be considered separately.
Keywords: accumulation; bone; depletion; toxicity; trace elements; uraemia
Notes
Correspondence and offprint requests to: Raymond Vanholder, MD, University Hospital Gent, Department of Internal Medicine, Nephrology Division, De Pintelaan 185, B 9000 Gent, Belgium. Email: raymond.vanholder{at}rug.ac.be
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Woo, W. Krzyzanski, A.-M. Duliege, R. B. Stead, and W. J. Jusko Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers J. Clin. Pharmacol., January 1, 2008; 48(1): 43 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, L. Zuo, G. Xu, F. Wang, M. Wang, S. Wang, J. Lv, L. Liu, and H. Wang Community-based screening for chronic kidney disease among populations older than 40 years in Beijing Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1093 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Van Biesen, D. De Bacquer, F. Verbeke, J. Delanghe, N. Lameire, and R. Vanholder The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years Eur. Heart J., February 2, 2007; 28(4): 478 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lefebvre, M. S. Duh, S. Buteau, B. Bookhart, and S. H. Mody Medical Costs of Untreated Anemia in Elderly Patients with Predialysis Chronic Kidney Disease J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3497 - 3502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Bennett, R. M. DeHart, and S. A. Lauderdale Survey of care provided by ambulatory care pharmacists to patients with chronic kidney disease. Am. J. Health Syst. Pharm., November 1, 2006; 63(21): 2123 - 2127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Q Hudson Secondary Hyperparathyroidism in Chronic Kidney Disease: Focus on Clinical Consequences and Vitamin D Therapies Ann. Pharmacother., September 1, 2006; 40(9): 1584 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.S. MacGregor, D.E. Boag, and A. Innes Chronic kidney disease: evolving strategies for detection and management of impaired renal function QJM, June 1, 2006; 99(6): 365 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Guallar, E. K. Silbergeld, A. Navas-Acien, S. Malhotra, B. C. Astor, A. R. Sharrett, and B. S. Schwartz Confounding of the Relation between Homocysteine and Peripheral Arterial Disease by Lead, Cadmium, and Renal Function Am. J. Epidemiol., April 15, 2006; 163(8): 700 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. de Lusignan, T. Chan, P. Stevens, D. O'Donoghue, N. Hague, B. Dzregah, J. Van Vlymen, M. Walker, and S. Hilton Identifying patients with chronic kidney disease from general practice computer records Fam. Pract., June 1, 2005; 22(3): 234 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schreiber Levocarnitine and Dialysis: A Review Nutr Clin Pract, April 1, 2005; 20(2): 218 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mircescu, D. Capsa, M. Covic, M. G. Caprioara, G. Gluhovschi, O. Golea, N. Ursea, L. Garneata, V. Cepoi, N. Constantinovici, et al. Nephrology and renal replacement therapy in Romania--transition still continues (Cinderella story revisited) Nephrol. Dial. Transplant., December 1, 2004; 19(12): 2971 - 2980. [Abstract] [Full Text] [PDF]
|
|